CMPX Compass Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why CMPX matters now
Compass Therapeutics, Inc. (CMPX) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.33 with +0.87% on the session and $322.2M in market capitalization; recent performance reads 1-month +11.60% and YTD -62.38%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-18.3M, and EPS of $-0.10. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -19.1%.
The latest indexable market news headline is "Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $9.00; recent insider activity includes Anderman Jonathan filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.02
P/S
0.00
EV/EBITDA
-3.49
DCF Value
$0.12
FCF Yield
-19.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-39.7%
ROA
-33.2%
ROIC
-38.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-18.3M | $-0.10 |
| Q4 2025 | $0.00 | $-15.7M | $-0.09 |
| FY 2025 | $0.00 | $-66.5M | $-0.42 |
| Q3 2025 | $0.00 | $-14.3M | $-0.10 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$10.40
Target (Median)
$9.00
Target Range
$6.00 - $15.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.74
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.